Loading clinical trials...
Loading clinical trials...
Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
panobinostat
carfilzomib
Locations
13
United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Florida Cancer Specialists South
Fort Myers, Florida, United States
Woodlands Medical Specialists
Pensacola, Florida, United States
Florida Cancer Specialists North
St. Petersburg, Florida, United States
Providence Medical Group
Terre Haute, Indiana, United States
RHHP/Hope Cancer Center
Terre Haute, Indiana, United States
Start Date
December 1, 2011
Primary Completion Date
December 1, 2020
Completion Date
December 1, 2020
Last Updated
February 2, 2022
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
SCRI Development Innovations, LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions